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Short Communication
Histochemical detection of oestrogen receptors in breast
carcinoma: A successful technique
R.A. Hawkins, K. Sangster & A. Krajewski
University Department ofClinical Surgery, Royal Infirmary ofEdinburgh and Department ofPathology, The
Medical School, Edinburgh, UK.
The heterogenous nature of breast tumours
(Hawkins et al., 1977; Silfversward et al., 1980)
complicates the application of oestrogen receptor
assay results to the management of breast cancer.
Much effort has therefore been expended on the
development of histochemical assays to detect
receptors in tissue sections, initially with oestrogen-
protein conjugates (e.g. Pertschuk et al., 1979; Lee,
1978 and Walker et al., 1980) and more recently
with antibodies against the receptor protein, both
polyclonal (e.g. Lope-Pihie et al., 1985; Tamura et
al., 1984) and monoclonal (Greene et al., 1980;
Coffer & King, 1981).
Few of these methods have been universally
accepted or validated in other centres (e.g.
McCarthy et al., 1980; Chamness, et al., 1980). In
our experience, too, both published (Penney &
Hawkins, 1982) and unpublished, we have
previously been unable to correlate histochemical
and biochemical assays. We therefore feel it is
important to report when a histochemical technique
does correlate with our established biochemical
assay.
One of the Greene-Jensen antibodies generated
against oestrogen receptor from MCF-7 breast
cancer cells is now marketed in the form of a kit
(ER-ICA) by Abbott Laboratories Ltd, and in our
hands, the results, in agreement with other reports,
are very promising.
Thirty-four breast cancers were received on ice
from operating theatres in the Edinburgh and Fife
regions within -1 h of excision. A portion of
tumour was cut from the face of the tissue and
fixed in formol-saline for routine histopathology, a
second portion (- 350mg) was used immediately
for biochemical assay of oestrogen receptor activity
by a standard DCC assay used in these laboratories
since November 1973 with one minor modification
(Hawkins et al., 1981) and a third smaller portion
(50-100mg) was frozen in liquid nitrogen until
assayed histochemically (within 12 weeks). For the
latter, 4 um frozen sections were cut, fixed,
incubated with either anti-receptor antibody (rat
IgG, 'test') or a control antibody (normal rat IgG)
and stained by a peroxidase-antiperoxidase tech-
nique, according to the manufacturer's instructions
(Abbott Laboratories, The Business Centre, Molly
Millar's Lane, Wokingham, Berks RGI 2QZ),
with particular care being taken to avoid drying-out
of the sections. In brief, the tissue sections were
fixed by immersion in formaldehyde (3.7%) in PBS
for 10min, in methanol at -20°C for 4min and in
acetone at -20°C for min, prior to incubations
at room temperature with normal goat serum
(15min), rat antibody (30min), 'bridging', goat
anti-rat antibody (30min), peroxidase-rat anti-
peroxidase complex (30min), and staining with
diamino benzidine plus hydrogen peroxide (6min).
When the peroxidase-staining reagents (DAB and
phosphate buffer - H202) ran out, the last few
specimens were stained using our own preparation
of DAB solution (1 mgmlP-I in tris-HCl buffer with
0.2% H202) containing imidazole (0.01 M). In each
run, at least one known, high receptor-positive
specimen was also processed (either the 'control'
cell slide provided by the manufacturer or a breast
cancer from our routine assays). Judging from these
control specimens, there was a little variation from
run to run. No striking effect of incorporating
imidazole was apparent, although staining intensity
was slightly increased.
Staining, when present, was confined to the
epithelial cell population and was virtually all
nuclear. The sections, it must be noted, did show
some cellular distortion, possibly due to the
triple fixation step employed. Within most sections,
there were both stained and unstained cells, plus
some variation in the intensity of staining amongst
the positive cells. In order to quantify staining,
each specimen was scored independently by each of
3 observers for (a) the cellularity (% of specimen
occupied by tumour cells), (b) the proportion (%)
of cells staining and (c) the average intensity of
staining (assessed on an arbitrary scale of-,
++,or +++).
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The results for the 34 breast cancers are shown in
Figure 1, where the histochemical assay result
(staining intensity) is plotted against the
biochemical assay result (fmol receptor sitesmg-1
protein). Of the tissues, 27 (i.e. 79%) were
biochemically receptor-positive and 7 (21%) were
receptor negative (i.e. <5fmol sitesmg-1 protein).
Histochemically, 25 (i.e. 74%) showed some
staining whilst the remaining 9 tissues, all with
biochemically determined receptor concentrations of
<10fmolmg-1 protein, showed no detectable trace
of staining. There was a strong correlation between
either the intensity of staining (Figure 1) or the
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Figure 1 The correlation between the histochemical
staining for oestrogen receptors ('staining intensity')
and receptor concentration as determined by a
standard biochemical assay in 34 breast cancers.
Staining intensity represents the mean of assessments
by 3 independent observers on an arbitrary scale of 0,
+, ++ and +++.r=+0.85.
percentage of cells staining (Figure 2) and
biochemical receptor site concentration, the
correlation coefficients being +0.85 and +0.87
respectively (Spearman's Rank Correlation Test,
n=34).
In this small series of tumours, biochemically-
determined receptor concentration on a protein
basis (fmol sitesmg-1 protein) was not significantly
related to the cellularity of the specimen assayed
(27 receptor-positive tissues only, correlation
coefficient =0.18, NS), though on a wet weight
basis, receptor concentration (fmolmg-I wet
tumour) was related to tumour cellularity (27
receptor-positive tissues only, correlation co-
efficient =0.40, P<0.05) as we have previously
shown (Hawkins et al., 1977, Masters et al., 1978,
Hawkins et al., 1981) and as might be expected
from the localisation of receptors in the epithelial
cells of the tumour.
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Figure 2 The correlation between the percentage of
cells staining histochemically for oestrogen receptors
and receptor concentration as determined bio-
chemically in 34 breast cancers. Percentage of cells
staining represents the mean of assessments by 3
independent observers. F= +0.87.
In the present study, although the tumour
cellularity differed between the portion selected for
histochemical assay and that selected for
biochemical assay, the differences were slight in 33
out of 34 tumours and severe in only one case (7%
vs. 37%). In order to facilitate comparison of
histochemical and biochemical results, a 'staining
index' (representing the total staining in the
specimen) was calculated as follows:
Staining index=Staining intensity x% cel g
100
% cellularity
100
(This was calculated using the cellularity of the
'biochemical specimen to minimise discrepancies due
to the use of non-identical portions of tissue in the
two assays). Staining index, too, was strongly
correlated with biochemically determined receptor
site concentration (correlation coefficient= +0.87,
P<0.001) as shown in Figure 3.
These results strongly suggest that the histo-
chemical assay described detects accurately the
classical oestrogen receptor as determined by
biochemical binding assays. Although others (King
et al., 1985; Thorpe et al., 1985; Pertschuk et al.,
1985; McLelland & Coombes, 1985; Harper et al.,
1985) have previously reported such a correlation,
we felt it important to report our confirmatory
findings after our previous disappointing
experiences with other assays of this type. From a
clinical point of view, although it may be difficult
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Figure 3 The correlation between histochemical
staining for oestrogen receptors, corrected for the
proportion of specimen not staining, and receptor
concentration determined biochemically in 34 breast
cancers. 'Staining index' =staining intensity x fraction
of tissue occupied by cells x fraction of cells staining.
In order to render histochemical and biochemical
assays comparable, staining index has been calculated
using the fraction of tissue occupied by cells in the
specimen used for biochemistry. F = +0.87.
to quantify histochemical assays precisely, the
assay, in our hands, starts to detect receptor
activity at concentrations around 20-40fmol
biochemical sitesmg-1 protein; this cut-off is fairly
close to that used routinely in this department for
treatment decisions (20fmolmg-1 protein) and is
very 'safe' as judged by other reports in relation to
treatment of advanced disease (Cant et al., 1985) or
adjuvant therapy (Rose et al., 1985; Stewart &
Prescott 1985). That the assay is as good as, or
better than, the biochemical procedure in
identifying responders to endocrine treatment in
advanced disease has already been demonstrated
directly by McLelland and Coombes (1985).
We consider these preliminary results to be
successful and believe that the technique shows
great potential for (i) assay of small specimens, (ii)
identification of tumours with a heterogeneous
population of cells with respect to receptor status
and (iii) application to cytological aspirates.
We wish to thank Mr R. McLelland and Dr R.C.
Coombes (Ludwig Institute for Cancer Research, London)
and Dr R.I. Nicholson (Tenovus Institute, Cardiff) for
helpful advice and discussion, and Miss A. Tesdale and
Mr W.A. Ferguson who performed the routine
biochemical assays.
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